Hemab Therapeutics Reports Positive Phase II Data for Sutacimig in Glanzmann Thrombasthenia
Hemab Therapeutics announced positive Phase II results from the CL-101 study of sutacimig for prophylactic treatment of Glanzmann thrombasthenia. Data presented at ASH 2025 showed clinically meaningful efficacy across bleed locations, types, and dose cohorts. The company plans to advance to Phase III.